TASIGNA 150 mg, hard capsule 28 capsules
Active ingredients: Nilotinib hydrochloride monohydrate, Nilotinib
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule28 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- TASIGNA 150 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- 7 plaquette(s) thermoformée(s) PVC PVDC aluminium de 4 gélule(s)
- Marketing authorisation holder
- NOVARTIS EUROPHARM (IRLANDE)
- Reimbursement according to BDPM
- 100%
- Reimbursement conditions
- Ce médicament peut être pris en charge ou remboursé par l'Assurance Maladie dans les cas suivants :<br><br>- Certains types de leucémies myéloïdes chroniques de l'adulte récemment diagnostiquées<br>- Certains types de leucémies myéloïdes chroniques de l'enfant, pour lesquelles l¿utilisation, comme traitement, de l'imatinib, a été un échec ; JOURNAL OFFICIEL ; 22/02/12
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 22 Feb 2012
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Initial prescription by a hospital doctor
- Initial prescription by a specialist
- Renewal by a specialist only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
63690098CIP74981584CIP133400949815845Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHLORHYDRATE DE NILOTINIB MONOHYDRATÉgélule | 165,45 mg · une gélule | SA |
| NILOTINIBgélule | 150 mg · une gélule | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.